Zobrazeno 1 - 10
of 28
pro vyhledávání: '"E Z Burnevich"'
Autor:
D T Abdurakhmanov, T P Rozina, E N Nikulkina, E Z Burnevich, E L Tanashuk, M V Severov, A L Filatova, S Yu Milovanova, V V Karpov, S V Moiseev
Publikováno v:
Терапевтический архив, Vol 91, Iss 11, Pp 110-115 (2019)
Exactly 30 years ago, hepatitis C virus was identified. Over the years, tremendous success has been achieved in the treatment of hepatitis C, which is currently considered to be an almost completely curable disease. The review presents the main stage
Externí odkaz:
https://doaj.org/article/e02f10f479164839adfb172f2dc8705e
Autor:
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk
Publikováno v:
Терапевтический архив, Vol 91, Iss 8, Pp 67-74 (2019)
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods. The study enrolled adult patients with HCV genotype 1b infection withou
Externí odkaz:
https://doaj.org/article/f1aba3c914e347cd9f3228d0e33775ff
Publikováno v:
Терапевтический архив, Vol 91, Iss 2, Pp 59-66 (2019)
Aim. To investigate risk factors of unfavorable prognosis in patients with chronic hepatitis C (CHC), including liver cirrhosis (LC), decompensated cirrhosis, hepatocellular carcinoma (HCC), cryoglobulinemic vasculitis (CryoVas) and B-cell non-Hodgki
Externí odkaz:
https://doaj.org/article/f287f9f7860c48e486762f2221e3c59b
Autor:
M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 41-51 (2018)
Aim of investigation. To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1s
Externí odkaz:
https://doaj.org/article/0686acb179664d0d893a6a2414c4957c
Publikováno v:
Акушерство, гинекология и репродукция, Vol 5, Iss 4, Pp 6-8 (2016)
Primary sclerosing cholangitis (PSC) is autoimmune disease characterized by inflammation and sclerosis of the bile duct, which leads to the development of secondary biliary cirrhosis. Many women with primary sclerosing cholangitis are at reproductive
Externí odkaz:
https://doaj.org/article/d641fbd9429e4376a5a6bbe2dbed0e8f
Autor:
E. Z. Burnevich
Publikováno v:
Журнал инфектологии, Vol 2, Iss 1, Pp 66-74 (2014)
Combination therapy with pegylated interferon-α and ribavirin is the modern standard of chronic hepatitis C treatment [1-3] in Russian Federation [4]. This particular regimen provides achieving of sustained virological response (SVR) in 42-28% of pa
Externí odkaz:
https://doaj.org/article/574bde1da2664cb2ada8ac60d39eb8f3
Autor:
D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 24, Iss 1, Pp 39-46 (2014)
Aim of investigation. HEP3002 is the international early access program of efficacy and safety estimation of telaprevir in combination to peginterferon alpha and ribavirin for patients with severe fibrosis or liver cirrhosis caused by hepatitis C vir
Externí odkaz:
https://doaj.org/article/f727f4d5f8664bfcb7a762333d267e4a
Autor:
E N Nikulkina, V.V. Karpov, E.L. Tanashuk, E Z Burnevich, D.T. Abdurakhmanov, A L Filatova, S Yu Milovanova, M.V. Severov, T. P. Rozina, S.V. Moiseev
Publikováno v:
Терапевтический архив, Vol 91, Iss 11, Pp 110-115 (2019)
Exactly 30 years ago, hepatitis C virus was identified. Over the years, tremendous success has been achieved in the treatment of hepatitis C, which is currently considered to be an almost completely curable disease. The review presents the main stage
Autor:
Vladimir Chulanov, E.P. Tarkhova, S N Batskikh, N. D. Yushchuk, S N Kizlo, Klimova Ea, E Z Burnevich, M.Yu. Samsonov, O. O. Znoyko, E.N. Krasavina, N A Mamonova, D.A. Gusev
Publikováno v:
Терапевтический архив, Vol 91, Iss 8, Pp 67-74 (2019)
Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C.The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistanc
Publikováno v:
Терапевтический архив, Vol 91, Iss 2, Pp 59-66 (2019)
Aim. To investigate risk factors of unfavorable prognosis in patients with chronic hepatitis C (CHC), including liver cirrhosis (LC), decompensated cirrhosis, hepatocellular carcinoma (HCC), cryoglobulinemic vasculitis (CryoVas) and B-cell non-Hodgki